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ABSTRACT
We present here the first update of the 2013 EFSUMB (Euro-
pean Federation of Societies for Ultrasound in Medicine and
Biology) Guidelines and Recommendations on the clinical use
of elastography with a focus on the assessment of diffuse liver
disease. The short version provides clinical information about
the practical use of elastography equipment and interpreta-
tion of results in the assessment of diffuse liver disease and
analyzes the main findings based on published studies, stres-
sing the evidence from meta-analyses. The role of elastogra-
phy in different etiologies of liver disease and in several clini-
cal scenarios is also discussed. All of the recommendations are
judged with regard to their evidence-based strength accord-
ing to the Oxford Centre for Evidence-Based Medicine Levels
of Evidence. This updated document is intended to act as a re-
ference and to provide a practical guide for both beginners
and advanced clinical users.
ZUSAMMENFASSUNG
Dies ist die erste Überarbeitung der 2013 publizierten EF-
SUMB-Leitlinien zur klinischen Anwendung der Elastografie
und konzentriert sich auf die diffusen Lebererkrankungen.
Der klinische Teil dieser Leitlinien erläutert die praktische An-
wendung der Elastografie bei der Beurteilung diffuser Leber-
erkrankungen unter Berücksichtigung der Geräteausstattung
und Interpretation der Ergebnisse. Die aktuelle Literatur
wurde analysiert unter besonderer Beachtung von Metaanaly-
sen. Die klinische Anwendung der Elastografie wird unter
Reflexion unterschiedlicher klinischer Szenarien und der
unterschiedlichen Ätiologien diffuser Lebererkrankungen
erläutert. Alle Empfehlungen erfolgten gemäß der Evidenz
basierten Methodik der Oxford-Klassifikation. Das hier vorges-
tellte Update soll dem Anfänger und fortgeschrittenen Nutzer
eine praktische Hilfe darstellen.
Introduction
The short version of this update of the 2013 EFSUMB (European
Federation of Societies for Ultrasound in Medicine and Biology)
Guidelines and Recommendations on the clinical use of shear
wave elastography provides information about the practical use
of elastography equipment and interpretation of results in
the assessment of diffuse liver disease and analyzes the main find-
ings based on published studies, stressing evidence from meta-
analyses.
The long version also includes an update of the section on the
basic principles of elastography, which now includes transient
elastography (TE) as a shear wave elastography (SWE) method,
and there are additional discussions of issues such as depth of
penetration, whether to perform measurements in units of kilo-
pascal (kPa) or ms–1, and the comparability of data from different
systems.
Investigator education
EFSUMB is working to promote high quality in ultrasound educa-
tion and sustain excellent professional standards in elastography
training and practice [1]. To ensure the lowest possible intrao-
perator variability, EFSUMB recommends that ultrasound elasto-
graphy be performed by operators that have passed competence
Level 1. However, it may also be possible to train dedicated
personnel to perform elastographic measurements only [2].
The basic principles and technology for elastography were
developed by the academic research community before commer-
cial translation, and it remains a heavily researched and rapidly
developing field. EFSUMB recommends that users maintain an
awareness of this field.
RECOMMENDATION 1
The operator must acquire appropriate knowledge and train-
ing in ultrasound elastography (LoE 5, GoR C). Strong consen-
sus (13/0/0, 100%)
RECOMMENDATION 2
Data acquisition should be undertaken by dedicated and spe-
cially trained personnel. For pSWE and 2D-SWE, experience in
B-mode ultrasound is mandatory (LoE 5, GoR C). Strong con-
sensus (13/0/0, 100%)
Shear wave elastography (TE, pSWE and
2D-SWE), general technical comments
Introduction
The liver is an important target organ for the use of elastography;
stiffness correlates with the degree of fibrosis and indirectly with
portal hypertension (see liver application).
Examination procedure
Subjects should be examined in a supine position with the right
arm in maximal extension. The transducer is positioned in a right
intercostal space to visualize the right liver lobe in A or B mode.
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Artefacts and large vessels on the A-mode (TE) or B-mode image
(pSWE and 2D-SWE) should be avoided. Optimal measurement
quality of pSWE and 2D-SWE occurs with the ROI placed a mini-
mum of 1 – 2 cm and a maximum of 6 cm beneath the liver cap-
sule [3 – 6]. A transient breath hold in a neutral position is optimal.
RECOMMENDATION 3
Measurement of liver stiffness by SWE should be performed
through a right intercostal space in supine position, with
the right arm in extension, during breath hold, avoiding deep
inspiration prior to the breath hold (LoE 2b, GoR B) [7, 8].
Strong consensus (18/0/0, 100%)
RECOMMENDATION 4
Measurement of liver stiffness by SWE should be performed
by experienced operators (LoE 2b, GoR B) [7, 8]. Strong con-
sensus (18/0/0, 100%)
RECOMMENDATION 5
Measurement of liver stiffness by pSWE and 2D-SWE should
be performed at least 10mm below the liver capsule (LoE 1b,
GoR A) [3 – 6, 8 – 11]. Strong consensus (18/0/0, 100%)
Fasting and resting
Food ingestion increases measurement readings (independent
of fibrosis) for an estimated 120 – 180 minutes after the meal
[12 – 14]. The examination should ideally be performed after an
overnight fast, while abstaining from food/drinks (especially
caffeine) and smoking. In addition, since exercise increases liver
stiffness, subjects should be examined after a minimum of 10 –
20 minutes of rest [15].
RECOMMENDATION 6
Patients should fast for a minimum of 2 hours and rest for a
minimum of 10 minutes before undergoing liver stiffness
measurement with SWE (LoE 2b, GoR B) [7]. Majority consen-
sus (13/2/3, 72%)
Factors influencing liver stiffness independent of
liver fibrosis (confounders)
Liver stiffness does not solely reflect liver fibrosis, but can reflect
many other physiological or pathological conditions. Liver stiff-
ness is increased with hepatic inflammation (often but not
exclusively shown by an elevated transaminase level) [16 – 19],
obstructive cholestasis [20] and hepatic congestion [21, 22].
For patients with falsely elevated liver stiffness measurements
(LSMs) due to alcoholic hepatitis, liver stiffness decreases follow-
ing 1 – 4 weeks of abstinence [23 – 25]. Other diseases, which
cause increased liver stiffness, independent of liver fibrosis
include amyloidosis, lymphomas and extramedullary hemopoi-
esis. Presently, it is uncertain whether hepatic steatosis modulates
liver stiffness [26, 27] or does not [28, 29].
RECOMMENDATION 7
The major potential confounding factors (liver inflammation
indicated by AST and/or ALT elevation > 5 times the normal
limits, obstructive cholestasis, liver congestion, acute hepa-
titis and infiltrative liver diseases) should be excluded before
performing LSM with SWE, in order to avoid overestimation
of liver fibrosis (LoE 2b, GoR B), and/or should be considered
when interpreting the SWE results (LoE 1b, GoR B) [16 – 21,
23 – 25, 30 – 33]. Broad consensus (15/0/1, 94%)
Normal values
TE measurements of Young’s modulus in healthy people vary
between 4.4 and 5.5 kPa (95th percentile 6.7 kPa) [34 – 37]. LSMs
are generally higher in men than in women [34, 35] and may be
affected by steatosis [34] but are not influenced by age [36, 37].
pSWE measurements using Virtual Touch Quantification
(VTQ®) in healthy populations range between 1.01 and 1.59m/s,
but in most studies the range is 1.07 – 1.16m/s [9, 10, 38 – 43].
Age has no apparent influence on the shear wave speed (SWS)
assessed by VTQ® [38, 39, 43]. All but one study [9] similarly
found no correlation between gender or body mass index (BMI)
and SWS values. Depth as assessed by the skin-to-liver capsule dis-
tance may influence the SWS values assessed by VTQ® [38]. In
healthy children, the mean SWS obtained in the right liver lobe
was 1.07 ± 0.10m/s in one study [44] and 1.12m/s (range: 0.73
to 1.45m/s) in another [45].
Values obtained with Elastography point quantification
(ElastPQ®) in healthy people are comparable to those obtained
with VTQ® [46 – 48], although in contrast to VTQ® findings, meas-
urements using ElastPQ® were 8% higher in healthy men than in
healthy women [48].
2D-SWE measurements of Young’s modulus using supersonic
shear imaging (SSI) in healthy subjects cover the range 4.5 – 5.5
kPa (95th percentile 6.2 kPa) [49, 50]. Healthy menmay have high-
er LSMs than healthy women, while BMI and age do not seem to
influence LSM in subjects without liver disease [50].
For all equipment, a SWE measurement within the normal
range, in a subject without other clinical or laboratory evidence
of liver disease, may exclude significant liver fibrosis with a high
degree of certainty.
The current literature has been recently summarized [51].
RECOMMENDATION 8
SWE within the normal range can rule out significant liver
fibrosis when in agreement with the clinical and laboratory
background (LoE 2A, GoR B) [34, 35]. Broad consensus (17/
0/1, 94%)
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Transient elastography (TE)
Procedure
Transient elastography uses an ultrasound displacement M-mode
and A-mode image produced by the system. The operator locates
a portion of the liver at least 6 cm thick and free of large vascular
structures. By pressing the acquisition button, the machine
displays the median of the measured Young’s modulus in kPa,
the interquartile range (IQR) (the difference between the 75th
and the 25th percentile), IQR/median (IQR/M), the value of the
current measurement and, only in the old version of the system,
the success rate (the ratio between valid and total number of
acquisitions). The system displays a result only if the acquisition
is valid, since the software automatically rejects acquisitions with-
out correct vibration shape or a correct follow-up of the vibration
propagation [7, 8, 52].
For children as well as in adults with a thoracic circumference
≤ 75 cm, the S probe is recommended, either S1 for a thoracic
circumference < 45 cm or S2 for 45 – 75 cm [53].
How to measure?
Following the manufacturer’s recommendation, assessment is
reliable when 10 valid readings and an IQR ≤ 30% of the median
(IQR/M ≤ 30 %) are obtained. The majority of studies have used
these reliability criteria as well as a success rate ≥ 60%. However,
these criteria have not been externally validated. A reliable TE
assessment can be achieved in over 90 % of adults, when both
the M and XL probes are used as required [54 – 57]. Because the
M probe takes measurements between 25 and 65mm from the
probe, to increase viability, those patients with a skin-to-liver
capsule distance (SCD) of > 25mm should be assessed with the
XL probe.
The diagnostic accuracy of the XL probe appears similar to that
of the M probe but the Young’s modulus values are lower than
those obtained with the M probe by a mean of 1.5 kPa (range of
0.8 – 2.3 kPa) [54 – 58].
RECOMMENDATION 9
10 measurements should be obtained. An IQR/M ≤ 30% of the
10 measurements is the most important reliability criterion
(LoE 1b, GoR A) [59, 60]. Strong consensus (17/0/0, 100%)
RECOMMENDATION 10
Values obtained with the XL probe are usually lower than with
the M probe. Therefore, no recommendation on the cut-offs
to be used can be given (LoE 2B, GoR B) [(54 – 57, 61)]. Broad
consensus (13/1/3, 77%)
Reproducibility
The intra- and interobserver agreements are excellent, with
reported intraclass correlation coefficients (ICC) above 0.90
[62 – 64]. The agreement decreases in overweight patients or in
early stages of fibrosis [62, 63]. Although the LSM seems to be
reproducible at different examination sites, the best examination
site is the median axillary line on the first intercostal space under
the liver percussion dullness upper limit, with the patient lying in
dorsal decubitus [63].
Point shear wave elastography (pSWE)
Experience with point shear wave elastography (pSWE) has been
mainly acquired with the VTQ® product, because it was the first
method available, subsequently followed by ElastPQ® and, more
recently, by pSWE methods from many companies.
Procedure (how to measure?)
The operator can select the depth at which liver elasticity is
evaluated by placing a “measuring box” (size depending on the
manufacturer) in the right liver lobe (segment V, VIII or VII), via
an intercostal approach and with the transducer at 90° in relation
to the liver capsule, in an area free of large vessels. In a pSWE
study using VTQ® to measure SWS [3], the best correlation with
histological fibrosis was observed for measurements performed
1 – 2 cm and 2 – 3 cm beneath the liver capsule (0.675 and 0.714,
respectively), but in up to 15% of cases, measurements could not
be obtained if performed 2 –3 cm under the liver capsule.
RECOMMENDATION 11
Adequate B-mode liver image is a prerequisite for pSWE and
2D-SWE measurements (LoE 5, GoR D). Strong consensus
(18/0/0, 100%)
How many measurements?
Most studies perform 10 valid measurements by pSWE and report
the median of these values. A few studies have used only 5 [65,
66] or 6 [67] valid measurements. Another study [68] calculated
the mean and standard deviation (SD) of 10 valid measurements.
A high SD correlated with misclassification of fibrosis. Additional-
ly, higher stages of fibrosis were associated with a higher SD,
indirectly indicating that "more" measurements should be obtain-
ed in patients with suspected fibrosis.
RECOMMENDATION 12
The median value of at least 10 measurements should be used
for liver elastography by pSWE (LoE 2b, GoR B) [68]. Strong
consensus (18/0/0, 100%)
Reproducibility
pSWE has excellent intra- and interoperator reproducibility for
liver elastography assessment in both healthy subjects and
patients with chronic liver disease [42, 46, 48, 69 – 71].
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Quality criteria
One study [72] evaluated factors that influenced the correlation
of SWS assessed by VTQ® with histological fibrosis in a cohort
of 106 chronic hepatitis C (CHC) patients. In univariate and multi-
variate analysis, an IQR/M ≥ 30 % was associated with a discor-
dance of at least 2 stages of fibrosis between SWS and histological
fibrosis. Using ElastPQ®, a recent study has suggested that an IQR/
M ≤ 30 % is the most important quality criterion, whereas the
number of measurements seems not to affect the performance,
provided that they are at least five [73]. Thus, the compliance
with quality criteria may increase the diagnostic accuracy of
pSWE [68, 72]. Quality parameters have been described for other
manufacturers as well [74].
2D-SWE
Almost all 2D-SWE studies for liver applications have been carried
out using SSI, because other companies have only recently intro-
duced 2D-SWE products. This description is therefore limited
to the SSI system, but the principles may be applied to other
2D-SWE products.
Procedure
Obtaining an elastogram
2D-SWE evaluation should be performed in a well-visualized area
of the right liver lobe, free of large vessels, liver capsule, ligaments
and the gallbladder [75]. Since movement greatly influences
results, the subject is asked to suspend breathing.
With 2D-SWE working in continuous and not with single shot
emissions, the SWE acquisition is continued for 4 – 5 seconds (can
be longer for other scanning systems) once a stable SWE image is
obtained. The operator should aim to achieve homogeneous color
filling of the SWE ROI. Usually a Young’s modulus scale of up to
30 kPa is sufficient, but a higher scale of up to 150 kPa can be adop-
ted on a case-by-case basis. The operator freezes the image (and
optionally saves the clip for further post-processing) and an analysis
box (Q Box, for SSI) is placed on the most homogeneous, stable
elastogram for a few seconds to measure Young’s modulus (SWS,
if the scanner is set to that mode).
How to measure?
Analysis box size and shape
For 2D-SWE measurements, the analysis box should be set to at
least 10mm, preferably 15mm or more. A round shape is usually
chosen [31, 32]. The ROI should be placed over an isoechoic area
of liver parenchyma, as seen on the grayscale image (no vessel, no
nodule, no other structure), in priority in the middle line of the
elastogram (avoiding positioning the Q Box on the edges of the
elastogram), while also avoiding SWS artefactual areas (reverbera-
tion, noisy areas from rib shadowing).
Valid and invalid measurements
There is no agreement on objective quality criteria. Some authors
suggest that a minimal Young’s modulus value of ≤ 0.2 kPa in
the analyzed region is useful to identify invalid measurements as
indicated by a lack of concordance with TE [76], while others use a
minimal Young’s modulus value of < 1 kPa. Furthermore, among
valid measurements an IQR/M ≤ 30 % is recommended by other
studies mimicking TE reliability criteria. For 2D-SWE with Logiq
E9 (GE), the manufacturer recommends an IQR/M below 30% as
a quality criterion. Temporal stability of the elastogram for three
seconds or more during breath hold in combination with place-
ment of the analysis box in a homogeneous area with complete
filling results in high accuracy, high reliability and low variance of
measurements with SSI [77 – 79]. The new software version of the
Aixplorer® system also shows the stability index (SI) and according
to the manufacturer a reliable LSM should exclude measurements
with an SI < 90%. Aplio 500 (Toshiba) provides a display of shear
waves travelling within the box, allowing selection of areas not
affected by artefacts for analysis. For 2D-SWE with the Philips sys-
tem, a confidence map guides the operator to perform measure-
ments in areas where the signal-to-noise ratio of the SWS assess-
ment is high.
How many measurements?
From 3 to 15 measurements are used in published studies, but
data from several studies suggest that 3 measurements suffice
to obtain consistent results for the assessment of liver fibrosis
and portal hypertension, and for optimal correlation with TE
[6, 32, 33, 79 – 81]. There is no convincing evidence to suggest
superiority of the mean versus median of the SSI measurements.
However, since the median and IQR are robust against non-nor-
mal distributed data, they should be preferred for reporting.
RECOMMENDATION 13
For 2D-SWE a minimum of three measurements should be
obtained; the final result should be expressed as the median
together with the interquartile range (LoE 2b, GoR B) [6, 82].
Strong consensus (18/0/0, 100%)
Reproducibility
Reproducibility in healthy subjects
In three studies, the intraobserver reproducibility of SSI during
the same session was excellent (ICC ranged from 0.92 to 0.95)
[49, 83, 84]. The interobserver agreement on different days was
affected by operator experience and ranged from 0.63 to 0.84
[83, 84].
Reproducibility in patients
The intraobserver reproducibility of 2D-SWE for liver stiffness as-
sessment in liver fibrosis patients is excellent, with the ICC ranging
from 0.90 to 0.95 in published studies [30, 31, 82]. The intra-sub-
ject reproducibility (evaluated over periods of 2 days to 4 weeks)
ranges between 0.83 and 0.90 [85]. Interobserver reproducibility
on the same day ranges from 0.83 [85] to 0.94 [77]. Intra- and
interobserver variance may be inferior to pSWE using VTQ® [85].
381Dietrich CF et al. EFSUMB Guidelines and… Ultraschall in Med 2017; 38: 377–394
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 L
a 
Sa
pi
en
za
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
Limitations
Failures
Common causes of failure are: depth below 4 – 5 cm [5], poor
ultrasound window, reverberations, pulsatile movement, poor
breath hold, large amounts of ascites [82], intercostal wall thick-
ness ≥ 25mm [86], BMI ≥ 30 kg/m2, histological steatosis and
waist circumference ≥ 102 cm [31, 33].
Unreliable assessments
The main factors limiting the applicability of 2D-SWE include
obesity, poor acoustic window or presence of artefacts and inabil-
ity of the subjects to hold their breath [5, 30, 31, 33, 82].
Comparison of results between systems
Introduction
Different US-based SWS technologies are available for the nonin-
vasive assessment of liver fibrosis and the measurements
produced can be slightly to moderately different between sys-
tems from different manufacturers. Even systems that use the
same technique but were developed by different manufacturers
can yield different values due to different and proprietary meth-
ods to measure the SWS.
Studies on phantoms
The Ultrasound Shear Wave Speed technical committee of the
Radiological Society of North America, Quantitative Imaging
Biomarker Alliance (QIBA) has quantified the differences between
commercially available systems. Working on elastic phantoms, a
statistically significant difference in the SWS estimates among
systems and depth of measurement in the phantom was shown,
whereas no statistically significant differences were found among
operators using the same or equivalent systems under the same
conditions [87]. Similar results were obtained using phantoms
with viscoelastic properties similar to those observed in normal
and fibrotic liver [88]. The measurements were performed at
multiple focal depths (3.0, 4.5 and 7.0 cm). The deepest focal
depth (7.0 cm) produced the greatest inter-system variability for
each phantom (up to 17.7 %) as evaluated by the interquartile
range. Inter-system variability was consistent across all phantoms
and was not related to stiffness.
Sources of variability
Several sources of variability are detailed in published studies,
including technical and patient-dependent factors that could
affect comparability between systems.
Technical factors
Measurement depth
As shown by the studies on phantoms [87], the influence of depth
on the estimation of elastic properties is not negligible. Further-
more, with curved transducers used in liver imaging, the angle af-
fects the readings, with the best results being achieved when the
ROI is straight ahead. Using VTQ®, it has been shown that the
results with the lowest variability are obtained at a depth of 4 –
5 cm with a convex transducer (1 – 4 MHz; mean push pulse:
2.67MHz) and at a depth of 2 – 3 cm with a linear transducer
(4 – 9 MHz; mean push pulse: 4 MHz) [89]. The acoustic push
pulse is progressively attenuated as it traverses the tissue.
Attenuation is higher in a stiffer liver. Thus, measurements are
more variable in cirrhotic patients [4].
Frequency of the transducer
In a prospective study on 89 patients with CHC, pSWE (based on
VTQ®) was performed using both available transducers (4C1 and
9L4) [90]. The linear transducer gave higher values (1.91
± 0.87 m/s vs. 1.70 ± 0.67 m/s). However, the results were
correlated to each other (r = 0.70). Using the same method in a
phantom and a series of eight volunteers, it was found that the
convex transducer showed values that were significantly higher
than those obtained with the linear transducer [89].
Position of the transducer
The highest intra- and interobserver agreement was obtained
for the measurements performed through the intercostal space
rather than the subcostal approach [48, 69, 91].
Operator experience
Methods using pSWE have shown excellent interobserver agree-
ment, with concordance ranging from 0.80 to 0.97 for measure-
ments performed via an intercostal approach, and independent
of operator experience, suggesting that operators require only a
short period of training to perform reliably LSMs [42, 46, 69, 92].
Using 2D-SWE (SSI) an expert operator had higher reproducibility
of measurements over time than a novice operator [84]. It is
suggested that at least 50 supervised 2D-SWE measurements
should be performed by a novice operator in order to obtain
consistent measurements. Echosens, the manufacturer of the
FibroScan device, recommends that TE be performed by an
experienced operator (> 100 examinations). Using liver biopsy as
the reference standard, a recent study has shown that ElastPQ®
matched TE for accuracy after the operator had performed
at least 130 examinations [93].
Equipment
Proprietary elastographic technologies generally give different
estimates of the SWS within the same liver. This translates into
the need to define threshold values for fibrotic stages for each
specific equipment model.
Clinical studies
Diagnostic accuracy
Some comparative studies show similar accuracy for different
elastographic systems. Larger prospective studies are necessary
to find if there are differences in accuracy between each different
system for liver stiffness evaluation.
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RECOMMENDATION 14
The results with the lowest variability in comparing different
pSWE or 2D-SWE systems were obtained at a depth of 4 –
5 cm from the transducers (with convex transducers) (LoE 4,
GoR C) [89]. Accordingly, this location is recommended if it is
technically suitable. Broad consensus (17/0/1, 94%)
Liver diseases
Introduction
The assessment of fibrosis in chronic liver diseases is pivotal for
prognosis and guiding management, including whether to com-
mence antiviral treatment. Liver biopsy is considered the “gold
standard” for fibrosis assessment and stage classification and can
also grade necro-inflammatory activity. However, liver biopsy is
limited by its invasiveness, sampling error and the inter- and
intraobserver variability in microscopic evaluation. Therefore,
noninvasive methods for liver fibrosis assessment including ultra-
sound elastographic methods have been an intense field of
research [7].
Due to the differences among elastography methods outlined
in previous sections, cut-off values for fibrosis are system-specific
and cannot be equated across machines.
It is becoming increasingly clear that the best cut-off values of
the different elastography techniques used to evaluate the pres-
ence and severity of liver fibrosis depend upon the etiology of
the underlying liver disease, and upon the prevalence of the con-
dition under study in the target population. Differences between
cut-offs may be simply related to differences in cirrhosis preval-
ence and severity in the studied populations, known as the
spectrum bias. Therefore, elastography values should be inter-
preted by a liver specialist aware of the clinical aspects of the liver
disease to be assessed and aware of the peculiarities of elastogra-
phy in general and each elastography technique in particular.
Besides increasing evidence regarding liver stiffness measured
by different techniques to detect liver fibrosis and cirrhosis
(described in detail in the following paragraphs), other new appli-
cations of elastography are being tested in the field of liver
diseases. They include spleen stiffness assessment for portal
hypertension and the evaluation of the stiffness of focal liver
lesions to differentiate between benign and malignant nodules.
These applications appear promising, but remain under develop-
ment and cannot yet be recommended in clinical practice.
Clinical needs
The ranges for intermediate fibrosis stages (F2-F3) are quite
narrow, in the order of a Young’s modulus of 2 –3 kPa (over a total
range spanning 2 to 75 kPa with the TE), so that small differences
in outputs could shift the assessment of patients from one stage
to another [94]. However, in “the real life” situation, attention
should be focused on the patient and what is appropriate from a
clinical point of view. Following the availability of novel antiviral
agents, the European Association for the Study of the Liver
(EASL) together with the Asociación Latinoamericana para el
Estudio del Hígado (ALEH) have produced guidelines for the
clinical use of noninvasive tests for the evaluation of liver disease
severity and prognosis [52]. These guidelines have outlined that
the two clinically relevant endpoints in patients with viral hepatitis
are the detection of significant fibrosis (F≥ 2) and the detection of
cirrhosis (F = 4), and the most important endpoint is the detection
of cirrhosis, because it guides treatment (A1 recommendation). In
patients with NAFLD and with chronic liver diseases of other etiol-
ogies, the detection of cirrhosis is also the most important clinical
endpoint (A1 recommendation).
Chronic hepatitis C (CHC)
Fibrosis staging
Transient elastography
In patients with CHC, TE can differentiate absent and mild fibrosis
from significant fibrosis and cirrhosis, but is not accurate enough
to distinguish between separate stages of fibrosis (F1-F4) [95 –
97]. A Young’s modulus greater than 6.8 – 7.6 kPa indicates a
high probability of significant fibrosis (F ≥ 2) on biopsy. However,
optimal cut-off values vary considerably depending on fibrosis
prevalence and may range between 5.2 – 9.5 kPa as indicated in
the clinical practice guidelines of the EASL [52]. Accordingly,
the optimal cut-off values for predicting cirrhosis (F = 4) range
between 11 and 15 kPa [52]. Therefore, the local fibrosis preval-
ence and the diagnostic aim (sensitive screening vs. secure exclu-
sion strategies) must be considered when adapting cut-off values
for clinical use. It should be emphasized that TE gives the best
diagnostic performance in the context of cirrhosis diagnosis, and
for this purpose it is better at ruling out than at ruling in cirrhosis.
In CHC patients with HIV co-infection, TE can be used with
similar diagnostic accuracy as compared to HCV infection alone
for fibrosis and cirrhosis detection [98]. TE can also be helpful in
liver transplant recipients for the staging of recurrent fibrosis and
cirrhosis [99].
The use of TE for the diagnosis of cirrhosis and the estimation
of fibrosis severity in CHC has been endorsed in the recommenda-
tions for the management of viral hepatitis by the EASL and the
ALEH, ideally in combination with an alternative and unrelated
noninvasive approach such as laboratory tests/serum markers of
fibrosis [100]. In the case of TE failure or inconclusive noninvasive
test results, biopsy is still recommended when fibrosis staging is
relevant for clinical decisions, although a preliminary attempt
with an alternative SWE method could be considered.
RECOMMENDATION 15
TE can be used as the first-line assessment for the severity of
liver fibrosis in patients with chronic viral hepatitis C. It per-
forms best with regard to the ruling out of cirrhosis (LoE 1b,
GoR A) [4, 98, 100]. Broad consensus (17/0/1, 94%)
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Point shear wave elastography (pSWE)
As with TE, VTQ® SWS quantification has been studied extensively
in patients with CHC. Cut-offs of 1.21 – 1.34m/s predict signifi-
cant fibrosis (F ≥ 2) (AUROC 0.85 – 0.89), while VTQ® cut-offs
between 1.55 and 2m/s (AUROC 0.89 – 0.93) predict cirrhosis
[70, 101]. The diagnostic performance of VTQ® is comparable
to TE [102] with high accuracy for predicting significant (F ≥ 2,
AUROC 0.87) and severe fibrosis (F ≥ 3, AUROC 0.91) as well as
cirrhosis (AUROC 0.93) [103]. However, discordance (>one fibrosis
stage) between VTQ® and histology occurred in > 30% in a study
including 106 patients infected with HCV. The discordance was
associated with female gender and a high interquartile range
(IQR/M ≥ 30%) of Young’s modulus [72]. Therefore, pSWE results
require cautious interpretation. Evidence regarding ElastPQ® is
limited [46, 104]. The results in the pilot study [46] for fibrosis
staging are similar to those reported for VTQ®, but more data
are needed. Fibrosis biomarkers may help to clarify indistinct
cases [105].
RECOMMENDATION 16
pSWE as demonstrated with VTQ® can be used as the first-line
assessment for the severity of liver fibrosis in patients with
chronic hepatitis C. It performs best with regard to the ruling
out of cirrhosis (LoE 2a, GoR B) [103]. Broad consensus (17/0/
1, 94%)
2D shear wave elastography (2D-SWE)
2D-SWE using SSI was reported in several studies in patients with
CHC [106, 107]. Diagnostic accuracy was high for the detection
of significant and advanced fibrosis and cirrhosis (AUC> 0.90).
In these studies the diagnostic performance for 2D-SWE was bet-
ter than for TE [106, 108] and serum fibrosis markers (FIB-4 index,
APRI and Forns' index) [108]. In one study including 102 obese
CHC patients, 2D-SWE had excellent diagnostic accuracy for the
detection of severe fibrosis and cirrhosis (AUROC > 0.90 for both)
[109].
RECOMMENDATION 17
2D-SWE as demonstrated with SSI can be used as a first-line
assessment for the severity of liver fibrosis in patients with
chronic hepatitis C. It performs best with regard to the ruling
out of cirrhosis (LoE 1b, GoR A) [106 – 108]. Broad consensus
(17/0/1, 94%)
Prediction of hepatic complications
Growing evidence supports the use of TE for risk stratification and
the prediction of clinical endpoints. Liver stiffness predicts 5-year
mortality with better accuracy than histological fibrosis staging
(METAVIR) for HCV mono-infected (TE > 9.5 kPa) [110] and HIV
co-infected patients (TE > 9.0 kPa) [111]. Furthermore, an elevat-
ed Young’s modulus indicates an increased risk of hepatocellular
carcinoma (HCC) development (TE > 10 kPa) [112], hepatic
decompensation and variceal bleeding [113]. Especially for
patients with an established diagnosis of cirrhosis, TE can be
used for grouping patients into different risk classes [112]. The
combination of liver stiffness (Young’s modulus of > 14 kPa) with
platelet count (< 141 × 103/μL) and response to antiviral treatment
may increase the predictive value of TE for HCC development
[114]. In patients with compensated liver cirrhosis, liver stiffness
helps to identify patients with portal hypertension (see section
recommendations on portal hypertension). Data regarding firm
endpoint prediction using pSWE and 2D-SWE are lacking and no
evidence-based recommendation can be specified. Two groups
evaluated the predictive value of TE in transplant patients with a
recurrence of HCV infection [115, 116]. A Young’s modulus > 8.7
kPa at 12 months after liver transplantation was associated with a
significantly reduced five-year graft and cumulative patient
survival [115].
Role of elastography in the setting of anti-HCV treatments
Role of SWE to identify patients to be treated
In the absence of universal access to direct-acting antiviral agents
(DAA) as a consequence of high cost, different countries have
implemented strategies to prioritize patients for treatment. TE
is used as the first-line investigation for the prioritization of
HCV patients for DAA (e. g., Young’s modulus values ≥ 7.1 kPa
are considered equivalent to fibrosis ≥F2, and values ≥ 9.5 kPa
are considered equivalent to fibrosis ≥F3). In countries using inter-
feron-based strategies, TE can help to identify patients with cir-
rhosis who have a lower likelihood of achieving a sustained virolo-
gical response (SVR: undetectable HCV-RNA, 24 weeks after
completion of antiviral therapy).
Role of SWE during treatment (monitoring)
Limited evidence in the setting of interferon-based therapy
postulated that increasing liver stiffness as measured by TE during
the treatment period might indicate a reduced possibility of
achieving a sustained virological response [117, 118]. Data in
patients undergoing IFN-free antiviral therapies suggest that liver
stiffness rapidly declines during treatment, even in patients with
advanced fibrosis and cirrhosis. This decline appears to reflect
the reduction in liver inflammation, restoration of liver function
and the decrease in portal pressure, like an effect of HCV eradica-
tion [119, 120].
Role of SWE after treatment (monitoring in follow-up)
Data regarding the usefulness of liver stiffness monitoring during
antiviral therapy are scant. In the largest prospective study pub-
lished (n = 91), a significant liver stiffness decrease was observed
during therapy with peg-interferon and ribavirin; the decrease in
liver stiffness continued after treatment only in patients who
achieved SVR [121]. In the era of DAAs, it is important to remark
that after successful HCV eradication, the use of pre-treatment
cut-off values can impair the accuracy of TE [122, 123], and it
might lead to erroneous conclusions if the SVR status is not care-
fully taken into account [120]. Several studies have evaluated
the use of VTQ® for monitoring IFN-based antiviral therapy in
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HCV patients: SWE decrease or increase reflects response or
no response to treatment, respectively [124 – 126]. For IFN-free
antiviral therapies, no data are available.
The monitoring of cirrhotic patients after SVR will become the
new standard in the era of DAAs. Although it is tempting to use
SWE in this setting to observe the dynamics of liver stiffness over
time, no recommendation can be made at this stage on cut-offs
and the time interval to identify cirrhosis regression.
RECOMMENDATION 18
SWE is not recommended to monitor fibrosis changes during
anti-HCV treatment (LoE 3, GOR D) [122, 123]]. Strong con-
sensus (18/0/0, 100%)
RECOMMENDATION 19
LSM changes after successful anti-HCV treatment should not
affect the management strategy (e. g. surveillance for HCC
occurrence in patients at risk) (LoE 3, GOR D) [52]. Broad con-
sensus (16/0/1, 94%)
Chronic hepatitis B (CHB)
Introduction
A large amount of evidence regarding elastography in CHB is avail-
able. There are > 50 published studies. The majority of them
use TE but also validate the elastographic methods of pSWE and
2D-SWE.
Fibrosis staging
The most important goal of noninvasive diagnostic tools is diag-
nosis of compensated cirrhosis that would benefit from treatment
regardless of the transaminase level [127].
Transient elastography
Transient elastography is the most validated elastographic meth-
od for staging CHB and has similar accuracy in this clinical sce-
nario compared to CHC [52]. Three meta-analyses confirmed the
good performance of TE in CHB staging [128 – 130]. Despite
LSMs showing a substantial overlap among adjacent stages of
fibrosis (particularly at lower fibrosis stages), LSM may effectively
identify patients with ≥F2 and F4. Recent publications confirmed
previous evidence, suggesting that the AUROCs for ≥F2 vary
between 0.80 and 0.90 [131, 132] with Young’s modulus cut-off
values between 6.6 kPa and 8.8 kPa [132, 133]. Regarding the
identification of cirrhosis (F4), recent data confirm previous
evidence, with AUROCs ranging between 0.81 and 0.97 [132]
and cut-off values between 9.4 and 13.4 kPa [134, 135]. A recent
meta-analysis suggested that a value > 11.7 kPa should raise
suspicion of cirrhosis [128]. It has been suggested that LSM
cut-offs should be adapted to transaminase levels [135] since
transaminase levels tend to influence LSM in CHB, and hepatitis
flares are often observed in CHB. However, recent studies showed
that ALT-adapted cut-offs do not influence TE diagnostic perform-
ance [136] and that the only variable associated with overestima-
tion of F4 stage in CHB is moderate/severe necro-inflammatory
activity without any direct correlation with transaminase levels
[137]. Interestingly, a Young’s modulus of < 5 kPa in patients
with normal ALT and low serum HBV DNA levels (< 2000 IU/ml)
characterize inactive HBV carriers [138, 139]. TE can be used to
rule out significant fibrosis and cirrhosis in HBV inactive carriers,
which is the best indication for TE in HBV.
RECOMMENDATION 20
TE is useful in patients with CHB to identify those with cirrho-
sis. Concomitant assessment of transaminases is required to
exclude flare up (elevation > 5 times upper limit of normal).
(LoE 1b, GoR A) [128 – 130]. Broad consensus (17/1/0, 94%)
RECOMMENDATION 21
TE is useful in inactive HBV carriers to rule out fibrosis (LoE 2,
GOR B) [138, 139]. Strong consensus (18/0/0, 100%)
Point shear wave elastography (pSWE)
VTQ® has the advantage of a lower failure rate and has a similar
diagnostic performance as TE. The discriminative ability for stag-
ing fibrosis in CHB is good, with AUROCs for ≥F2 and F4 of 0.76 –
0.91 [134, 140] and 0.72 – 0.97 [103, 134], respectively. These
findings were confirmed in a meta-analysis that included patients
with several etiologies of liver disease. The analysis of data of
patients with CHB showed an AUROC for ≥F2 of 0.88 and the
best cut-off was 1.35m/s and the AUROC for F4 was 0.93 and
the best cut-off was 1.87m/s [141, 142]. There is limited data
about other pSWE methods. ElastPQ® has been used for staging
CHB patients in four studies, with good performance for staging
liver fibrosis. Further validation is required [92, 142 – 144].
2D shear wave elastography (2D-SWE)
Recently, 2D-SWE (SSI) was tested in patients with CHB and
proved to have a lower failure rate than TE and at least similar
performance for fibrosis staging [145]. The AUROC for ≥F2 varies
between 0.85 and 0.91 [32, 146], with Young’s modulus cut-offs
between 7.1 and 8.0 kPa [145, 146], while the AUROC for F4
varies between 0.92 and 0.98 [147, 145], with optimal cut-offs
between 10.1 and 11.7 kPa [32, 145]. The best indications of
2D-SWE in HBV are inactive carriers to rule out significant fibrosis
and cirrhosis diagnosis.
RECOMMENDATION 22
pSWE as demonstrated with VTQ® is useful in patients with
CHB to identify those with cirrhosis (LoE 2a, GoR B) [141].
Strong consensus (18/0/0, 100%)
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RECOMMENDATION 23
2D-SWE as demonstrated with SSI is useful in patients with
CHB to identify those with cirrhosis (LoE 3a, GoR C) [146,
147]. Broad consensus (17/0/1, 94%)
Monitoring (evaluation of) response to treatment
Under nucleoside/nucleotide analogs, liver stiffness measured by
TE significantly decreases regardless of the baseline values of
ALT [148, 149]. The only factors associated with decline of LSM
are higher baseline LSM and HBV DNA levels [148]. The diagnostic
accuracy and thresholds of liver stiffness using TE may differ in
untreated and treated patients with chronic hepatitis B and C.
This aspect should be taken into account when interpreting the
results of elastography. Moreover, even if liver stiffness declines
with antiviral treatment, it is unknown if this reflects disease
regression and LSM changes should not affect management.
RECOMMENDATION 24
LSM changes under HBV treatment should not affect the
management strategy (e. g. surveillance for HCC occurrence
in patients at risk) (LoE 2b, GOR B) [148, 149]. Strong consen-
sus (16/0/0, 100%)
Prognostic relevance
Baseline LSM by TE has modest prognostic relevance with an AUR-
OC between 0.70 and 0.73 for liver-related events [150, 151],
which may be increased by adding spleen diameter and platelet
count as a prediction model called LSPS (= LSM × spleen diame-
ter/platelet count) up to a level of 0.83 [152]. TE is a good prog-
nostic marker for HCC development that may occur without
cirrhosis. A Young’s modulus of > 8 kPa might be a value indicating
the need to start screening for HCC, even if a complete virological
response was achieved [153, 154]. The risk of HCC is even higher if
the Young’s modulus by TE is > 12 – 13 kPa, which also implies an
increased risk of decompensation [131, 153 – 155].
Non-alcoholic fatty liver disease (NAFLD)
In NAFLD patients, noninvasive markers should aim at the follow-
ing: a) identify the risk of NAFLD/NASH among individuals with
metabolic syndrome; b) identify those with a worse prognosis;
c) monitor disease progression; d) predict response to treatment.
Fibrosis staging (NAFLD)
Transient elastography
TE performance is better for cirrhosis than for significant fibrosis
[156, 157]. TE has a higher rate of false-positive than false-nega-
tive results and a higher negative predictive value (NPV) than
positive predictive value (PPV). Therefore, the ability to diagnose
bridging fibrosis or cirrhosis is insufficient for clinical decision-
making [158, 159]. A systematic review of TE in patients with
NAFLD involved 9 studies and 1047 patients [160]. TE was excel-
lent in diagnosing F3 fibrosis (85% sensitivity, 82% specificity) and
cirrhosis (92% sensitivity, 92% specificity), but had only moderate
accuracy for F2 fibrosis (79% sensitivity, 75% specificity).
With the M probe, patients with steatosis > 66% at liver biopsy
had higher LSM values, which led to higher false-positive LSM
results [26]. Thus, in obese patients with a high degree of steato-
sis, TE (using the M probe) may be less accurate in diagnosing
severe fibrosis in NAFLD, and additional evaluation may be war-
ranted to avoid overestimation of fibrosis. However, additional
studies on the effects of steatosis on LSM measured with an XL
probe are needed. The XL probe produces lower stiffness values
than the M probe. Different cut-offs should be used [57]. With
the M probe, at a Young’s modulus cut-off value of 7.9 kPa, the
sensitivity, specificity, PPV and NPV for F3 or greater disease are
91%, 75%, 52%, and 97%, respectively [29].
In NAFLD patients, the best cut-off for F3 or greater disease is
7.2 kPa. With this cut-off, the NPV to exclude F3 or greater disease
is 89 % (95% CI 84 – 95%). Cut-off values of 5.7 kPa and 9.3 kPa
have 90 % sensitivity and specificity to rule out and rule in F3
disease, respectively [29].
RECOMMENDATION 25
TE can be used to exclude cirrhosis in NAFLD patients (LoE 2a,
GoR B) [52, 160]. Broad consensus (13/0/3, 81%)
Point shear wave elastography (pSWE)
A systematic review of 7 studies for a total of 723 patients who
underwent SWS measurements with VTQ® technique to evaluate
the diagnostic efficacy of pSWE in patients with NAFLD was
recently published [161]. The summary sensitivity was 80.2 % for
detecting significant fibrosis, which is not an appropriate
endpoint.
2D shear wave elastography (2D-SWE)
There are only two studies that evaluate the performance of
2D-SWE (SSI) [31, 162]. The results are too limited to make
recommendations.
Comparison of different elastographic methods for NAFLD
One study recently compared TE (using the M probe), pSWE
(VTQ®) and 2D-SWE (SSI) in 291 patients with NAFLD enrolled in
two different hospitals [31]. All methods showed AUROCs
≥ 0.84 for severe fibrosis and cirrhosis and had a similar perfor-
mance for the diagnosis of these endpoints. The diagnostic per-
formance of 2D-SWE was superior to that of VTQ® for the diagno-
sis of significant fibrosis.
Follow-up of patients
Monitoring of the progression of fibrosis is also necessary in the
follow-up of these patients. Patients who achieved a ≥ 5% weight
loss at the 6-month follow-up showed a decrease in LSM by TE,
independent of the changes in aminotransferase levels [158]. No
data are available for pSWE and 2D-SWE.
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Prediction of liver-related complications
A recent study supports the use of TE for risk stratification and
prediction of clinical endpoints [163]. For pSWE and 2D-SWE
data on this aspect are lacking and no evidence-based recommen-
dation can be given.
Alcoholic liver disease (ALD)
Fibrosis staging
Transient elastography in patients with prior or current chronic
alcohol overuse can distinguish absent and mild fibrosis (F0 – 1)
from severe fibrosis and cirrhosis, but similar to other etiologies,
there is no evidence to suggest that it can differentiate absent
and mild fibrosis from significant fibrosis. [164] Additionally, in
the eight published single etiology studies on TE for staging liver
fibrosis, there is no consensus regarding optimal Young’s modulus
cut-off values for significant fibrosis (≥F2), severe fibrosis (≥F3) or
cirrhosis (= F4) [23, 30, 165 – 170]. The optimal cut-off values
range from 7.8 [166] to 9.6 [30] kPa for significant fibrosis, from
8.0 [23] to 17.0 [168] kPa for severe fibrosis and from 12.5 [23] to
22.7 [165] kPa for cirrhosis. The considerable discrepancy
between cut-off values in individual studies is likely a conse-
quence of differences in fibrosis stage prevalence with overrepre-
sentation of cirrhotic patients, place of recruitment, and whether
patients with alcoholic hepatitis or decompensated disease were
excluded.
TE is more suited to rule out than rule in cirrhosis. At a Young’s
modulus of 12.5 kPa, TE may rule out cirrhosis with a negative
likelihood ratio of 0.07 if the disease prevalence is 50% or lower
[164].
RECOMMENDATION 26
TE can be used to exclude cirrhosis in patients with alcoholic
liver disease, provided that acute alcoholic hepatitis is not
present (LoE 2b, GoR B) [30, 164, 169, 170]. Strong consensus
(15/0/0, 100%)
Prognostication of alcoholic liver cirrhosis
There is scant evidence to suggest a role for ultrasound elastogra-
phy for determining the prognosis and for the monitoring of
patients with alcoholic liver disease [171], or for TE to predict
esophageal varices [172] and the hepatic venous pressure gradi-
ent in patients with alcoholic cirrhosis [171].
Timing of liver stiffness measurements with regard
to alcohol abstinence
In patients undergoing alcohol detoxification, 0.5 to 4 weeks of
abstinence causes a clinically significant decrease in TE [23 – 25,
173]. However, the decrease is associated with a normalization
of transaminases, bilirubin, alkaline phosphatase and/or gamma-
glutamyltransferase. It is, therefore, unclear whether alcohol
alone or alcohol-induced hepatitis and cholangiocyte damage
cause the increase in liver stiffness. [170]. One study suggests
that TE is accurate for staging in patients with ongoing alcohol
abuse but normal gamma-glutamyltransferase [30], while
another study suggests that AUROC for the diagnosis of cirrhosis
in alcoholic patients diminishes when AST is above 100 – 150U/L
[170].
Screening the general population or high-risk groups
in primary care
Ultrasound elastography for systematic screening of high-risk
populations in primary care for alcoholic liver disease was per-
formed in one study. TE was offered to primary care patients
with an AST:ALT ratio ≥ 0.8 [174]. However, this study did not in-
clude biopsy confirmation in patients with elevated TE. In a diag-
nostic study, TE had excellent diagnostic accuracy for significant
fibrosis and cirrhosis in a subgroup of 71 patients recruited from
primary alcohol rehabilitation centers [30].
With a prevalence of cirrhosis of 2 – 4% in a background popu-
lation of at-risk individuals [175], the positive predictive value of
TE should be considered low regardless of cut-off values.
Point shear wave elastography (pSWE) and 2D-SWE
There is only one study to support the use of 2D-SWE (SSI) for
assessing alcoholic liver fibrosis [30]. There are three small studies
on the use of pSWE [176 – 178], two of which report diagnostic
accuracies and test probabilities. The results are consistent
regarding diagnostic accuracy, which suggests that VTQ® may be
used to rule out severe fibrosis and cirrhosis. The results regarding
cut-off values are, however, inconsistent. Therefore, there is insuf-
ficient evidence to make recommendations for using VTQ® to
distinguish absent and mild fibrosis (F0 – 1) from significant or
severe fibrosis and cirrhosis. Thus, there is still insufficient evi-
dence to evaluate the role of pSWE or 2D-SWE in alcoholic liver
disease.
Cholestatic liver disease and autoimmune hepatitis (AIH)
Risk stratification is a major need in patients with chronic chole-
static diseases in order to allow personalized management and
the selection of candidates for clinical trials of new drugs. Studies
of liver stiffness as a surrogate of liver fibrosis and prognosis
focusing on cholestatic liver disease (primary biliary cholangitis-
PBC, primary sclerosing cholangitis-PSC) or AIH are scarce. Most
available data focus on TE [179 – 181].
Transient elastography
Transient elastography is currently considered one of the best
surrogates of fibrosis in PBC. High baseline or increasing values
over time indicate a worse outcome in this population [141,
179]. Liver stiffness was investigated in 73 patients with PSC, reg-
ularly undergoing clinical and elastographic follow-up [182]. LSMs
were able to differentiate severe vs. non-severe fibrosis with a
high discriminative accuracy for cirrhosis (AUROC 0.88). There
was high reproducibility between two operators. Higher baseline
LSM and an increase of LSM over time were associated with
adverse outcome such as death, liver transplantation, ascites,
hepatic encephalopathy, gastrointestinal bleeding, or HCC [182].
Dilatation of the intrahepatic biliary system due to a dominant
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stricture should be excluded in PSC before interpreting the LSMs.
Cholestasis increases liver stiffness independent of liver fibrosis.
Data regarding the pediatric population with biliary atresia
suggest that liver (and spleen) elastography could be a valuable
tool to predict outcomes before surgery, and might be used after
the Kasai operation to monitor liver disease and portal hyperten-
sion [183].
Due to the limited evidence, no recommendation can be given.
Point shear wave elastography (pSWE)
VTQ® was initially performed in 9 patients with AIH, PBC and PSC
having higher shear wave velocities than healthy volunteers [184].
In total, two studies dealt with VTQ® in AIH and primary biliary
cholangitis. In 15 patients with treated AIH, VTQ® could differ-
entiate between the absence of fibrosis and significant fibrosis
[185]. SWS assessed by VTQ® showed good diagnostic accuracy
for detecting cirrhosis (AUROC 0.91) in 61 patients with primary
biliary cholangitis [186].
2D shear wave elastography (2D-SWE)
Data regarding 2D-SWE in AIH, PBC and PSC are not available.
Liver stiffness assessment helped in differentiating between bili-
ary atresia and neonatal hepatitis in one study [187].
Due to the paucity of data, no recommendation can be given.
Portal hypertension
Transient elastography
In patients with compensated advanced chronic liver disease/
cirrhosis, LSM correlates with the hepatic venous pressure gradi-
ent (HVPG). Even though the correlation between the two does
not allow for an accurate estimate of the exact HVPG value
(range: 0.59 – 0.70), the discriminative ability of liver stiffness for
the presence of clinically significant portal hypertension (CSPH,
defined as HVPG ≥ 10mmHg, threshold for the appearance of
complications) is very high, with a summary AUROC of 0.93 in a
recent meta-analysis [188]. However, it should be emphasized
that most of the patients included in the studies concerning
HVPG had viral or alcoholic cirrhosis, and evidence regarding
other etiologies is limited. In viral cirrhosis, Young’s modulus
values of > 20 – 25 kPa are highly specific for CSPH, and values of
> 21 kPa predict the onset of a first clinical decompensation with
an accuracy similar to that of HVPG > 10mmHg [189].
RECOMMENDATION 27
LSM with TE is useful to identify patients with a high likelihood
of having clinically significant portal hypertension (HVPG
≥ 10mmHg) (LoE 2b, GoR B) [188, 189]. Strong consensus
(15/0/0, 100%)
The accuracy of LSM in predicting the presence and size of gastro-
esophageal varices has been the subject of several studies.
Despite the fact that it is currently the best single noninvasive
predictor in this field with summary AUROCs of 0.84 for esopha-
geal varices (EV) and 0.78 for large EV in a recent meta-analysis
[188], the cut-offs vary widely among the studies, and the accura-
cy is not sufficient to replace endoscopy. The accuracy of LSM for
the diagnosis of CSPH and varices improves if it is combined with
platelet count and spleen size [190, 191]. Recent data indicates
that if a combination of a Young’s modulus value of < 20 kPa and
a platelet count of > 150 G/L is used, varices needing treatment
can be ruled out with a high accuracy (< 5 % of patients missed)
[192, 193], and endoscopy can be safely avoided [194].
Point shear wave elastography (pSWE)
Point SWE (VTQ®) has been used in three studies addressing the
diagnosis of CSPH [195 – 197] and showed excellent applicability
and very good diagnostic accuracy (AUROC 0.82 – 0.90). VTQ®
has been used in a few studies addressing the diagnosis and sever-
ity of esophageal varices. SWS was higher in patients with esoph-
ageal varices of any size, and was even higher in patients with
large varices [195, 196]. However, reliable cut-offs are not avail-
able yet. No strong recommendation regarding the cut-offs to be
used can be made due to the limited evidence.
2 D shear wave elastography (2D-SWE)
2D-SWE (SSI) has been tested for the diagnosis of CSPH in 4 stud-
ies and a further small series [6, 198 – 201]. The accuracy of the
method was reliable in all of the published studies (AUROC
0.80 – 0.92).
Two studies performed a head-to-head comparison between
LSM by TE and 2D-SWE [6, 198]. TE was less applicable, and both
techniques showed similar accuracy for the diagnosis of CSPH.
LSM by 2D-SWE is higher in patients with esophageal varices of
any size and is further increased in patients with large varices.
However, reliable cut-offs are not available yet. No strong recom-
mendation regarding the cut-offs for 2D-SWE can be given, and
further evidence is needed.
RECOMMENDATION 28
Liver stiffness using TE combined with platelet count is useful
to rule out varices requiring treatment (LoE 2b, GoR B) [194].
Although preliminary results are encouraging, there is insuffi-
cient evidence to recommend pSWE and 2D-SWE in this set-
ting. Broad consensus (13/0/1, 93%)
Conflict of interest
Some authors declare conflicts of interest, which are available from the
publisher.
Acknowledgement
The authors thank the EFSUMB secretary Lynne Rudd for her never-end-
ing support of the EFSUMB guidelines. We also thank the following
companies for funding a consensus meeting of the authors held in Lon-
don in July 2016, at which we agreed the recommendations made in this
paper: bk/Ultrasound, Echosens, Esaote SpA, GE Healthcare, Hitachi
388 Dietrich CF et al. EFSUMB Guidelines and… Ultraschall in Med 2017; 38: 377–394
Guidelines & Recommendations
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 L
a 
Sa
pi
en
za
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
Medical Systems, Philips Healthcare, Shenzhen Mindray Bio-medical
Electronics Co., Ltd, Siemens Healthineers, SuperSonic and Toshiba
Medical. Representatives of these companies were in attendance at this
meeting, to assist with product technical information, but did not take
part in forming the manuscript or the recommendations.
References
[1] EFSUMB. Education and Professional Standards Committee (EPSC) Mini-
mum Training recommendations for the practice of medical ultrasound.
Ultraschall in Med 2006; 27: 79–105
[2] Fabrellas N, Alemany M, Urquizu M et al. Using transient elastography to
detect chronic liver diseases in a primary care nurse consultancy. Nurs
Res 2013; 62: 450–454
[3] Sporea I, Sirli RL, Deleanu A et al. Acoustic radiation force impulse elas-
tography as compared to transient elastography and liver biopsy in pa-
tients with chronic hepatopathies. Ultraschall in Med 2011; 32: S46–S52
[4] Barr RG, Ferraioli G, Palmeri ML et al. Elastography Assessment of Liver
Fibrosis: Society of Radiologists in Ultrasound Consensus Conference
Statement. Radiology 2015; 276: 845–861
[5] Wang CZ, Zheng J, Huang ZP et al. Influence of measurement depth on
the stiffness assessment of healthy liver with real-time shear wave elas-
tography. Ultrasound Med Biol 2014; 40: 461–469
[6] Procopet B, Berzigotti A, Abraldes JG et al. Real-time shear-wave elasto-
graphy: applicability, reliability and accuracy for clinically significant
portal hypertension. J Hepatol 2015; 62: 1068–1075
[7] Bamber J, Cosgrove D, Dietrich CF et al. EFSUMB guidelines and recom-
mendations on the clinical use of ultrasound elastography. Part 1: Basic
principles and technology. Ultraschall in Med 2013; 34: 169–184
[8] Ferraioli G, Filice C, Castera L et al. WFUMB guidelines and recommen-
dations for clinical use of ultrasound elastography: Part 3: liver. Ultra-
sound Med Biol 2015; 41: 1161–1179
[9] Liao LY, Kuo KL, Chiang HS et al. Acoustic radiation force impulse elasto-
graphy of the liver in healthy patients: test location, reference range and
influence of gender and body mass index. Ultrasound Med Biol 2015; 41:
698–704
[10] Goertz RS, Egger C, Neurath MF et al. Impact of food intake, ultrasound
transducer, breathing maneuvers and body position on acoustic radia-
tion force impulse (ARFI) elastometry of the liver. Ultraschall in Med
2012; 33: 380–385
[11] Goertz RS, Zopf Y, Jugl V et al. Measurement of liver elasticity with
acoustic radiation force impulse (ARFI) technology: an alternative non-
invasive method for staging liver fibrosis in viral hepatitis. Ultraschall
in Med 2010; 31: 151–155
[12] Mederacke I, Wursthorn K, Kirschner J et al. Food intake increases liver
stiffness in patients with chronic or resolved hepatitis C virus infection.
Liver Int 2009; 29: 1500–1506
[13] Arena U, Lupsor Platon M, Stasi C et al. Liver stiffness is influenced by a
standardized meal in patients with chronic hepatitis C virus at different
stages of fibrotic evolution. Hepatology 2013; 58: 65–72
[14] Berzigotti A, De Gottardi A, Vukotic R et al. Effect of meal ingestion on
liver stiffness in patients with cirrhosis and portal hypertension. PLoS
One 2013; 8: e58742
[15] Gersak MM, Sorantin E, Windhaber J et al. The influence of acute physical
effort on liver stiffness estimation using Virtual Touch Quantification
(VTQ). Preliminary results. Med Ultrason 2016; 18: 151–156
[16] Coco B, Oliveri F, Maina AM et al. Transient elastography: a new surro-
gate marker of liver fibrosis influenced by major changes of transami-
nases. J Viral Hepat 2007; 14: 360–369
[17] Sagir A, Erhardt A, Schmitt M et al. Transient elastography is unreliable
for detection of cirrhosis in patients with acute liver damage. Hepatolo-
gy 2008; 47: 592–595
[18] Arena U, Vizzutti F, Corti G et al. Acute viral hepatitis increases liver
stiffness values measured by transient elastography. Hepatology 2008;
47: 380–384
[19] Vigano M, Massironi S, Lampertico P et al. Transient elastography as-
sessment of the liver stiffness dynamics during acute hepatitis B. Eur
J Gastroenterol Hepatol 2010; 22: 180–184
[20] Millonig G, Reimann FM, Friedrich S et al. Extrahepatic cholestasis in-
creases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology
2008; 48: 1718–1723
[21] Millonig G, Friedrich S, Adolf S et al. Liver stiffness is directly influenced
by central venous pressure. J Hepatol 2010; 52: 206–210
[22] Colli A, Pozzoni P, Berzuini A et al. Decompensated chronic heart failure:
increased liver stiffness measured by means of transient elastography.
Radiology 2010; 257: 872–878
[23] Mueller S, Millonig G, Sarovska L et al. Increased liver stiffness in alco-
holic liver disease: differentiating fibrosis from steatohepatitis. World
J Gastroenterol 2010; 16: 966–972
[24] Trabut JB, Thepot V, Nalpas B et al. Rapid decline of liver stiffness fol-
lowing alcohol withdrawal in heavy drinkers. Alcohol Clin Exp Res 2012;
36: 1407–1411
[25] Bardou-Jacquet E, Legros L, Soro D et al. Effect of alcohol consumption
on liver stiffness measured by transient elastography. World J Gastroen-
terol 2013; 19: 516–522
[26] Petta S, Maida M, Macaluso FS et al. The severity of steatosis influences
liver stiffness measurement in patients with nonalcoholic fatty liver
disease. Hepatology 2015; 62: 1101–1110
[27] Macaluso FS, Maida M, Camma C et al. Steatosis affects the performance
of liver stiffness measurement for fibrosis assessment in patients with
genotype 1 chronic hepatitis C. J Hepatol 2014; 61: 523–529
[28] Yoneda M, Yoneda M, Mawatari H et al. Noninvasive assessment of liver
fibrosis by measurement of stiffness in patients with nonalcoholic fatty
liver disease (NAFLD). Dig Liver Dis 2008; 40: 371–378
[29] Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis and cirrhosis
using liver stiffness measurement in nonalcoholic fatty liver disease.
Hepatology 2010; 51: 454–462
[30] Thiele M, Detlefsen S, Sevelsted Moller L et al. Transient and 2-Dimen-
sional Shear-Wave Elastography Provide Comparable Assessment of
Alcoholic Liver Fibrosis and Cirrhosis. Gastroenterology 2016; 150: 123–
133
[31] Cassinotto C, Boursier J, De Ledinghen V et al. Liver stiffness in nonalco-
holic fatty liver disease: A comparison of Supersonic Shear Imaging,
FibroScan and ARFI with liver biopsy. Hepatology 2016; 63: 1817–1827
[32] Zeng J, Liu GJ, Huang ZP et al. Diagnostic accuracy of two-dimensional
shear wave elastography for the non-invasive staging of hepatic fibrosis
in chronic hepatitis B: a cohort study with internal validation. Eur Radiol
2014; 24: 2572–2581
[33] Cassinotto C, Lapuyade B, Mouries A et al. Noninvasive assessment of
liver fibrosis with impulse elastography: comparison of Supersonic Shear
Imaging with ARFI and Fibroscan. J Hepatol 2014; 61: 550–557
[34] Colombo S, Belloli L, Zaccanelli M et al. Normal liver stiffness and its de-
terminants in healthy blood donors. Dig Liver Dis 2011; 43: 231–236
[35] Roulot D, Costes JL, Buyck JF et al. Transient elastography as a screening
tool for liver fibrosis and cirrhosis in a community-based population
aged over 45 years. Gut 2011; 60: 977–984
[36] Corpechot C, El Naggar A, Poupon R. Gender and liver: is the liver stiff-
ness weaker in weaker sex? Hepatology 2006; 44: 513–514
[37] Sirli R, Sporea I, Tudora A et al. Transient elastographic evaluation of
subjects without known hepatic pathology: does age change the liver
stiffness? J Gastrointestin Liver Dis 2009; 18: 57–60
[38] Horster S, Mandel P, Zachoval R et al. Comparing acoustic radiation force
impulse imaging to transient elastography to assess liver stiffness in
389Dietrich CF et al. EFSUMB Guidelines and… Ultraschall in Med 2017; 38: 377–394
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 L
a 
Sa
pi
en
za
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
healthy volunteers with and without valsalva manoeuvre. Clin Hemor-
heol Microcirc 2010; 46: 159–168
[39] Karlas T, Pfrepper C, Wiegand J et al. Acoustic radiation force impulse
imaging (ARFI) for non-invasive detection of liver fibrosis: examination
standards and evaluation of interlobe differences in healthy subjects and
chronic liver disease. Scand J Gastroenterol 2011; 46: 1458–1467
[40] Popescu A, Bota S, Sporea I et al. The influence of food intake on liver
stiffness values assessed by acoustic radiation force impulse elastogra-
phy-preliminary results. Ultrasound Med Biol 2013; 39: 579–584
[41] Son CY, Kim SU, Han WK et al. Normal liver elasticity values using
acoustic radiation force impulse imaging: a prospective study in healthy
living liver and kidney donors. J Gastroenterol Hepatol 2012; 27: 130–
136
[42] Guzmán-Aroca F, Reus M, Berná-Serna JD et al. Reproducibility of shear
wave velocity measurements by acoustic radiation force impulse imag-
ing of the liver: a study in healthy volunteers. J Ultrasound Med 2011; 30:
975–979
[43] Toshima T, Shirabe K, Takeishi K et al. New method for assessing liver
fibrosis based on acoustic radiation force impulse: a special reference to
the difference between right and left liver. J Gastroenterol 2011; 46:
705–711
[44] Matos H, Trindade A, Noruegas MJ. Acoustic radiation force impulse
imaging in paediatric patients: normal liver values. J Pediatr Gastroen-
terol Nutr 2014; 59: 684–688
[45] Hanquinet S, Courvoisier D, Kanavaki A et al. Acoustic radiation force
impulse imaging-normal values of liver stiffness in healthy children.
Pediatr Radiol 2013; 43: 539–544
[46] Ferraioli G, Tinelli C, Lissandrin R et al. Point shear wave elastography
method for assessing liver stiffness. World J Gastroenterol 2014; 20:
4787–4796
[47] Sporea I, Bota S, Grădinaru-Taşcău O et al. Comparative study between
two point Shear Wave Elastographic techniques: Acoustic Radiation
Force Impulse (ARFI) elastography and ElastPQ. Med Ultrason 2014; 16:
309–314
[48] Ling W, Lu Q, Quan J et al. Assessment of impact factors on shear wave
based liver stiffness measurement. Eur J Radiol 2013; 82: 335–341
[49] Suh CH, Kim SY, Kim KW et al. Determination of normal hepatic elasti-
city by using real-time shear-wave elastography. Radiology 2014; 271:
895–900
[50] Huang Z, Zheng J, Zeng J et al. Normal liver stiffness in healthy adults
assessed by real-time shear wave elastography and factors that influ-
ence this method. Ultrasound Med Biol 2014; 40: 2549–2555
[51] Dong Y, Sirli R, Ferraioli G et al. Shear Wave Elastography of the liver,
review on normal values. Z Gastroenterol 2017; 55: 153–166
[52] European Association for Study of L, Asociacion Latinoamericana para el
Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests
for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63:
237–264
[53] Engelmann G, Gebhardt C, Wenning D et al. Feasibility study and control
values of transient elastography in healthy children. Eur J Pediatr 2012;
171: 353–360
[54] de Ledinghen V, Wong VW, Vergniol J et al. Diagnosis of liver fibrosis and
cirrhosis using liver stiffness measurement: comparison between M and
XL probe of FibroScan(R). J Hepatol 2012; 56: 833–839
[55] de Ledinghen V, Vergniol J, Foucher J et al. Feasibility of liver transient
elastography with FibroScan using a new probe for obese patients. Liver
Int 2010; 30: 1043–1048
[56] Durango E, Dietrich C, Seitz HK et al. Direct comparison of the FibroScan
XL and M probes for assessment of liver fibrosis in obese and nonobese
patients. Hepat Med 2013; 5: 43–52
[57] Wong VW, Vergniol J, Wong GL et al. Liver stiffness measurement using
XL probe in patients with nonalcoholic fatty liver disease. Am J Gastro-
enterol 2012; 107: 1862–1871
[58] Carrion JA, Puigvehi M, Coll S et al. Applicability and accuracy improve-
ment of transient elastography using the M and XL probes by experi-
enced operators. J Viral Hepat 2015; 22: 297–306
[59] Lucidarme D, Foucher J, Le Bail B et al. Factors of accuracy of transient
elastography (fibroscan) for the diagnosis of liver fibrosis in chronic
hepatitis C. Hepatology 2009; 49: 1083–1089
[60] Myers RP, Crotty P, Pomier-Layrargues G et al. Prevalence, risk factors
and causes of discordance in fibrosis staging by transient elastography
and liver biopsy. Liver Int 2010; 30: 1471–1480
[61] Myers RP, Pomier-Layrargues G, Kirsch R et al. Discordance in fibrosis
staging between liver biopsy and transient elastography using the Fi-
broScan XL probe. J Hepatol 2012; 56: 564–570
[62] Fraquelli M, Rigamonti C, Casazza G et al. Reproducibility of transient
elastography in the evaluation of liver fibrosis in patients with chronic
liver disease. Gut 2007; 56: 968–973
[63] Boursier J, Konate A, Gorea G et al. Reproducibility of liver stiffness
measurement by ultrasonographic elastometry. Clin Gastroenterol
Hepatol 2008; 6: 1263–1269
[64] Afdhal NH, Bacon BR, Patel K et al. Accuracy of fibroscan, compared with
histology, in analysis of liver fibrosis in patients with hepatitis B or C: a
United States multicenter study. Clin Gastroenterol Hepatol 2015; 13:
772–779 e771-e773
[65] Takahashi H, Ono N, Eguchi Y et al. Evaluation of acoustic radiation force
impulse elastography for fibrosis staging of chronic liver disease: a pilot
study. Liver Int 2010; 30: 538–545
[66] Rizzo L, Calvaruso V, Cacopardo B et al. Comparison of transient elasto-
graphy and acoustic radiation force impulse for non-invasive staging of
liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol
2011; 106: 2112–2120
[67] Piscaglia F, Salvatore V, Di Donato R et al. Accuracy of VirtualTouch
Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of
cirrhosis during liver ultrasonography. Ultraschall in Med 2011; 32:
167–175
[68] Goertz RS, Sturm J, Pfeifer L et al. S. ARFI cut-off values and significance
of standard deviation for liver fibrosis staging in patients with chronic
liver disease. Ann Hepato 2013; 12: 935–941
[69] D'Onofrio M, Gallotti A, Mucelli RP. Tissue quantification with acoustic
radiation force impulse imaging: Measurement repeatability and normal
values in the healthy liver. Am J Roentgenol 2010; 195: 132–136
[70] Friedrich-Rust M, Wunder K, Kriener S et al. Liver fibrosis in viral hepati-
tis: noninvasive assessment with acoustic radiation force impulse ima-
ging versus transient elastography. Radiology 2009; 252: 595–604
[71] Bota S, Sporea I, Sirli R et al. Intra- and interoperator reproducibility of
acoustic radiation force impulse (ARFI) elastography–preliminary re-
sults. Ultrasound Med Biol 2012; 38: 1103–1108
[72] Bota S, Sporea I, Sirli R et al. Factors which influence the accuracy of
acoustic radiation force impulse (ARFI) elastography for the diagnosis of
liver fibrosis in patients with chronic hepatitis C. Ultrasound Med Biol
2013; 30: 407–412
[73] Ferraioli G, Maiocchi L, Lissandrin R et al. Accuracy of the ElastPQ Tech-
nique for the Assessment of Liver Fibrosis in Patients with Chronic He-
patitis C: a "Real Life" Single Center Study. J Gastrointestin Liver Dis 2016;
25: 331–335
[74] Dietrich CF, Dong Y. Shear wave elastography with a new reliability indi-
cator. J Ultrason 2016; 16: 281–287
[75] Samir AE, Dhyani M, Vij A et al. Shear-wave elastography for the estima-
tion of liver fibrosis in chronic liver disease: determining accuracy and
ideal site for measurement. Radiology 2015; 274: 888–896
390 Dietrich CF et al. EFSUMB Guidelines and… Ultraschall in Med 2017; 38: 377–394
Guidelines & Recommendations
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 L
a 
Sa
pi
en
za
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
[76] Poynard T, Munteanu M, Luckina E et al. Liver fibrosis evaluation using
real-time shear wave elastography: applicability and diagnostic per-
formance using methods without a gold standard. J Hepatol 2013; 58:
928–935
[77] Cassinotto C, Charrie A, Mouries A et al. Liver and spleen elastography
using supersonic shear imaging for the non-invasive diagnosis of cirrho-
sis severity and oesophageal varices. Dig Liver Dis 2015; 47: 695–701
[78] Cassinotto C, de Lédinghen V. Reply to: “New imaging assisted methods
for liver fibrosis quantification: Is it really favorable to classical transient
elastography?”. J Hepatol 2015; 63: 767
[79] Thiele M, Madsen BS, Procopet B et al. Reliability criteria for liver stiffness
measurements with real-time 2D shear wave elastography in different
clinical scenarios of chronic liver disease. Ultraschall in Med 2016.
DOI: 10.1055/s-0042-108431
[80] Sporea I, Gradinaru-Tascau O, Bota S et al. How many measurements are
needed for liver stiffness assessment by 2D-Shear Wave Elastography
(2D-SWE) and which value should be used: the mean or median? Med
Ultrason 2013; 15: 268–272
[81] Sporea I, Bota S, Jurchis A et al. Acoustic radiation force impulse and
supersonic shear imaging versus transient elastography for liver fibrosis
assessment. Ultrasound Med Biol 2013; 39: 1933–1941
[82] Yoon JH, Lee JM, Han JK et al. Shear wave elastography for liver stiffness
measurement in clinical sonographic examinations: evaluation of in-
traobserver reproducibility, technical failure, and unreliable stiffness
measurements. J Ultrasound Med 2014; 33: 437–447
[83] Hudson JM, Milot L, Parry C et al. Inter- and intra-operator reliability and
repeatability of shear wave elastography in the liver: a study in healthy
volunteers. Ultrasound in Med & Biol 2013; 39: 950–955
[84] Ferraioli G, Tinelli C, Zicchetti M et al. Reproducibility of real-time shear
wave elastography in the evaluation of liver elasticity. Eur J Radiol 2012;
81: 3102–3106
[85] Woo H, Lee JY, Yoon JH et al. Comparison of the Reliability of Acoustic
Radiation Force Impulse Imaging and Supersonic Shear Imaging in
Measurement of Liver Stiffness. Radiology 2015; 277: 881–886
[86] Staugaard B, Christensen PB, Mossner B et al. Feasibility of transient
elastography versus real-time two-dimensional shear wave elastography
in difficult-to-scan patients. Scand J Gastroenterol 2016; 51: 1354–
1359
[87] Hall TJ, Milkowski A, Garra B et al. RSNA/QIBA: shear wave speed as a
biomarker for liver fibrosis staging. In: Ultrasonics Symposium (IUS),
2013. I.E. International. 2013: 397–400
[88] Palmeri M, Nightingale K, Fielding S et al. RSNA QIBA ultrasound shear
wave speed Phase II phantom study in viscoelastic media. Proceedings of
the 2015 IEEE Ultrasonics Symposium, 2015. International. 2013: 397–
400
[89] Chang S, Kim MJ, Kim J et al. Variability of shear wave velocity using
different frequencies in acoustic radiation force impulse (ARFI) elasto-
graphy: a phantom and normal liver study. Ultraschall in Med 2013; 34:
260–265
[90] Potthoff A, Attia D, Pischke S et al. Influence of different frequencies and
insertion depths on the diagnostic accuracy of liver elastography by
acoustic radiation force impulse imaging (ARFI). Eur J Radiol 2013; 82:
1207–1212
[91] Ferraioli G, Lissandrin R, Zicchetti M et al. Ultrasound point shear wave
elastography assessment of liver and spleen stiffness: effect of training
on repeatability of measurements. Eur Radiol 2014; 24: 1283–1289
[92] Ma JJ, Ding H, Mao F et al. Assessment of liver fibrosis with elastography
point quantification technique in chronic hepatitis B virus patients: a
comparison with liver pathological results. J Gastroenterol Hepatol
2014; 29: 814–819
[93] Fraquelli M, Baccarin A, Casazza G et al. Liver stiffness measurement
reliability and main determinants of point shear-wave elastography in
patients with chronic liver disease. Aliment Pharmacol Ther 2016; 44:
356–365
[94] Piscaglia F, Salvatore V, Mulazzani L et al. Ultrasound Shear Wave Elas-
tography for Liver Disease. A Critical Appraisal of the Many Actors on the
Stage. Ultraschall in Med 2016; 37: 1–5
[95] Friedrich-Rust M, Ong MF, Martens S et al. Performance of transient
elastography for the staging of liver fibrosis: a meta-analysis. Gastroen-
terology 2008; 134: 960–974
[96] Chang PE, Goh GB, Ngu JH et al. Clinical applications, limitations and
future role of transient elastography in the management of liver disease.
World J Gastrointest Pharmacol Ther 2016; 7: 91–106
[97] Tsochatzis EA, Gurusamy KS, Ntaoula S et al. Elastography for the diag-
nosis of severity of fibrosis in chronic liver disease: a meta-analysis of
diagnostic accuracy. J Hepatol 2011; 54: 650–659
[98] Njei B, McCarty TR, Luk J et al. Use of Transient Elastography in Patients
with HIV-HCV Co-infection: A Systematic Review and Meta-analysis.
J Gastroenterol Hepatol 2016; 31: 1684–1693
[99] Barrault C, Roudot-Thoraval F, Tran Van Nhieu J et al. Non-invasive as-
sessment of liver graft fibrosis by transient elastography after liver
transplantation. Clin Res Hepatol Gastroenterol 2013; 37: 347–352
[100] European Association for Study of L. EASL Clinical Practice Guidelines:
management of hepatitis C virus infection. J Hepatol 2014; 60: 392–
420
[101] Sporea I, Bota S, Peck-Radosavljevic M et al. Acoustic Radiation Force
Impulse elastography for fibrosis evaluation in patients with chronic
hepatitis C: an international multicenter study. Eur J Radiol 2012; 81:
4112–4118
[102] Friedrich-Rust M, Lupsor M, de Knegt R et al. Point Shear Wave Elasto-
graphy by Acoustic Radiation Force Impulse Quantification in Com-
parison to Transient Elastography for the Noninvasive Assessment of
Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multi-
center Study. Ultraschall in Med 2015; 36: 239–247
[103] Friedrich-Rust M, Nierhoff J, Lupsor M et al. Performance of Acoustic
Radiation Force Impulse imaging for the staging of liver fibrosis: a
pooled meta-analysis. J Viral Hepat 2012; 19: e212–e219
[104] Conti F, Serra C, Vukotic R et al. Accuracy of elastography point quan-
tification and steatosis influence on assessing liver fibrosis in patients
with chronic hepatitis C. Liver Int 2017; 37: 187–195
[105] Joo SK, Kim JH, Oh S et al. Prospective Comparison of Noninvasive
Fibrosis Assessment to Predict Advanced Fibrosis or Cirrhosis in Asian
Patients With Hepatitis C. J Clin Gastroenterol 2015; 49: 697–704
[106] Ferraioli G, Tinelli C, Dal Bello B et al. Accuracy of real-time shear wave
elastography for assessing liver fibrosis in chronic hepatitis C: a pilot
study. Hepatology 2012; 56: 2125–2133
[107] Bavu E, Gennisson JL, Couade M et al. Noninvasive in vivo liver fibrosis
evaluation using supersonic shear imaging: a clinical study on 113
hepatitis C virus patients. Ultrasound Med Biol 2011; 37: 1361–1373
[108] Tada T, Kumada T, Toyoda H et al. Utility of real-time shear wave elas-
tography for assessing liver fibrosis in patients with chronic hepatitis C
infection without cirrhosis: Comparison of liver fibrosis indices. Hepa-
tol Res 2015; 45: 122–129
[109] Yoneda M, Thomas E, Sclair SN et al. Supersonic shear imaging and
transient elastography with the XL probe accurately detect fibrosis in
overweight or obese patients with chronic liver disease. Clin Gastro-
enterol Hepatol 2015; 13: 1502–1509 e1505
[110] Vergniol J, Foucher J, Terrebonne E et al. Noninvasive tests for fibrosis
and liver stiffness predict 5-year outcomes of patients with chronic
hepatitis C. Gastroenterology 2011; 140: 1970–1979
391Dietrich CF et al. EFSUMB Guidelines and… Ultraschall in Med 2017; 38: 377–394
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 L
a 
Sa
pi
en
za
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
[111] Macias J, Camacho A, Von Wichmann MA et al. Liver stiffness mea-
surement versus liver biopsy to predict survival and decompensations
of cirrhosis among HIV/hepatitis C virus-coinfected patients. AIDS
2013; 27: 2541–2549
[112] Masuzaki R, Tateishi R, Yoshida H et al. Prospective risk assessment for
hepatocellular carcinoma development in patients with chronic hepa-
titis C by transient elastography. Hepatology 2009; 49: 1954–1961
[113] Poynard T, Vergniol J, Ngo Y et al. Staging chronic hepatitis C in seven
categories using fibrosis biomarker (FibroTest) and transient elasto-
graphy (FibroScan(R)). J Hepatol 2014; 60: 706–714
[114] Narita Y, Genda T, Tsuzura H et al. Prediction of liver stiffness hepato-
cellular carcinoma in chronic hepatitis C patients on interferon-based
anti-viral therapy. J Gastroenterol Hepatol 2014; 29: 137–143
[115] Crespo G, Lens S, Gambato M et al. Liver stiffness 1 year after trans-
plantation predicts clinical outcomes in patients with recurrent hepa-
titis C. Am J Transplant 2014; 14: 375–383
[116] Carrion JA, Navasa M, Bosch J et al. Transient elastography for diagnosis
of advanced fibrosis and portal hypertension in patients with hepatitis
C recurrence after liver transplantation. Liver Transpl 2006; 12: 1791–
1798
[117] Stasi C, Piluso A, Arena U et al. Evaluation of the prognostic value of
liver stiffness in patients with hepatitis C virus treated with triple or
dual antiviral therapy: A prospective pilot study. World J Gastroenterol
2015; 21: 3013–3019
[118] Yada N, Sakurai T, Minami T et al. Ultrasound elastography correlates
treatment response by antiviral therapy in patients with chronic hepa-
titis C. Oncology 2014; 87 (Suppl. 1): 118–123
[119] Mandorfer M, Kozbial K, Freissmuth C et al. Interferon-free regimens
for chronic hepatitis C overcome the effects of portal hypertension on
virological responses. Aliment Pharmacol Ther 2015; 42: 707–718
[120] Deterding K, Schlevogt B, Port K et al. Letter: can persisting liver stiff-
ness indicate increased risk of hepatocellular cell carcinoma after suc-
cessful anti-HCV therapy? – authors' reply. Aliment Pharmacol Ther
2016; 43: 546–547
[121] Hezode C, Castera L, Roudot-Thoraval F et al. Liver stiffness diminishes
with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther
2011; 34: 656–663
[122] Lee HW, Chon YE, Kim SU et al. Predicting Liver-Related Events Using
Transient Elastography in Chronic Hepatitis C Patients with Sustained
Virological Response. Gut Liver 2016; 10: 429–436
[123] D'Ambrosio R, Aghemo A, Fraquelli M et al. The diagnostic accuracy of
Fibroscan for cirrhosis is influenced by liver morphometry in HCV pa-
tients with a sustained virological response. J Hepatol 2013; 59: 251–
256
[124] Osakabe K, Ichino N, Nishikawa T et al. Changes of shear-wave velocity
by interferon-based therapy in chronic hepatitis C. World J Gastroen-
terol 2015; 21: 10215–10223
[125] Goertz RS, Sturm J, Zopf S et al. Outcome analysis of liver stiffness by
ARFI (acoustic radiation force impulse) elastometry in patients with
chronic viral hepatitis B and C. Clin Radiol 2014; 69: 275–279
[126] Yamada R, Hiramatsu N, Oze T et al. Significance of liver stiffness
measurement by acoustic radiation force impulse (ARFI) among hepa-
titis C patients. J Med Virol 2014; 86: 241–247
[127] Liver EAFTSOT. EASL clinical practice guidelines: Management of
chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185
[128] Chon YE, Choi EH, Song KJ et al. Performance of transient elastography
for the staging of liver fibrosis in patients with chronic hepatitis B: a
meta-analysis. PLoS One 2012; 7: e44930
[129] Xu X, Su Y, Song R et al. Performance of transient elastography asses-
sing fibrosis of single hepatitis B virus infection: a systematic review
and meta-analysis of a diagnostic test. Hepatol Int 2015; 9: 558–566
[130] Li Y, Huang YS, Wang ZZ et al. Systematic review with meta-analysis:
the diagnostic accuracy of transient elastography for the staging of
liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol
Ther 2016; 43: 458–469
[131] Seo YS, Kim MN, Kim SU et al. Risk Assessment of Hepatocellular Car-
cinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepa-
titis B Patients Receiving Antiviral Therapy. Medicine (Baltimore) 2016;
95: e2985
[132] Meng F, Zheng Y, Zhang Q et al. Noninvasive evaluation of liver fibrosis
using real-time tissue elastography and transient elastography (Fi-
broScan). J Ultrasound Med 2015; 34: 403–410
[133] Liu Y, Dong CF, Yang G et al. Optimal linear combination of ARFI, tran-
sient elastography and APRI for the assessment of fibrosis in chronic
hepatitis B. Liver Int 2015; 35: 816–825
[134] Dong DR, Hao MN, Li C et al. Acoustic radiation force impulse elasto-
graphy, FibroScan(R), Forns' index and their combination in the as-
sessment of liver fibrosis in patients with chronic hepatitis B, and the
impact of inflammatory activity and steatosis on these diagnostic
methods. Mol Med Rep 2015; 11: 4174–4182
[135] Chan HL, Wong GL, Choi PC et al. Alanine aminotransferase-based
algorithms of liver stiffness measurement by transient elastography
(Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009;
16: 36–44
[136] Cardoso AC, Carvalho-Filho RJ, Stern C et al. Direct comparison of
diagnostic performance of transient elastography in patients with
chronic hepatitis B and chronic hepatitis C. Liver Int 2012; 32: 612–
621
[137] Fraquelli M, Rigamonti C, Casazza G et al. Etiology-related determi-
nants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol
2011; 54: 621–628
[138] Invernizzi F, Vigano M, Grossi G et al. The prognosis and management
of inactive HBV carriers. Liver Int 2016; 36 (Suppl. 1): 100–104
[139] Castera L, Bernard PH, Le Bail B et al. Transient elastography and bio-
markers for liver fibrosis assessment and follow-up of inactive hepatitis
B carriers. Aliment Pharmacol Ther 2011; 33: 455–465
[140] Dong CF, Xiao J, Shan LB et al. Combined acoustic radiation force im-
pulse, aminotransferase to platelet ratio index and Forns index assess-
ment for hepatic fibrosis grading in hepatitis B. World J Hepatol 2016;
8: 616–624
[141] Nierhoff J, Chavez Ortiz AA, Herrmann E et al. The efficiency of acous-
tic radiation force impulse imaging for the staging of liver fibrosis: a
meta-analysis. Eur Radiol 2013; 23: 3040–3053
[142] Ding H, Ma JJ, Wang WP et al. Assessment of liver fibrosis: the rela-
tionship between point shear wave elastography and quantitative
histological analysis. J Gastroenterol Hepatol 2015; 30: 553–558
[143] Lu Q, Lu C, Li J et al. Stiffness values and serum biomarkers in liver
fibrosis staging: study in large surgical specimens in patients with
chronic Hepatitis B. Radiology 2016; 280: 290–299
[144] Yegin EG, Yegin K, Karatay E et al. Quantitative assessment of liver
fibrosis by digital image analysis: Relationship to Ishak staging and
elasticity by shear-wave elastography. J Dig Dis 2015; 16: 217–227
[145] Leung VY, Shen J, Wong VW et al. Quantitative elastography of liver
fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison
of shear-wave elastography and transient elastography with liver
biopsy correlation. Radiology 2013; 269: 910–918
[146] Feng JC, Li J, Wu XW et al. Diagnostic Accuracy of SuperSonic Shear
Imaging for Staging of Liver Fibrosis: A Meta-analysis. J Ultrasound Med
2016; 35: 329–339
[147] Li C, Zhang C, Li J et al. Diagnostic Accuracy of Real-Time Shear Wave
Elastography for Staging of Liver Fibrosis: A Meta-Analysis. Med Sci
Monit 2016; 22: 1349–1359
392 Dietrich CF et al. EFSUMB Guidelines and… Ultraschall in Med 2017; 38: 377–394
Guidelines & Recommendations
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 L
a 
Sa
pi
en
za
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
[148] Kim MN, Kim SU, Kim BK et al. Long-term changes of liver stiffness
values assessed using transient elastography in patients with chronic
hepatitis B receiving entecavir. Liver Int 2014; 34: 1216–1223
[149] Yo IK, Kwon OS, Park JW et al. The factors associated with longitudinal
changes in liver stiffness in patients with chronic hepatitis B. Clin Mol
Hepatol 2015; 21: 32–40
[150] Park MS, Kim SU, Kim BK et al. Prognostic value of the combined use of
transient elastography and fibrotest in patients with chronic hepatitis
B. Liver Int 2015; 35: 455–462
[151] Kim MN, Kim SU, Park JY et al. Risk assessment of liver-related events
using transient elastography in patients with chronic hepatitis B re-
ceiving entecavir. J Clin Gastroenterol 2014; 48: 272–278
[152] Shin SH, Kim SU, Park JY et al. Liver stiffness-based model for predic-
tion of hepatocellular carcinoma in chronic hepatitis B virus infection:
comparison with histological fibrosis. Liver Int 2015; 35: 1054–1062
[153] Wong GL, Chan HL, Wong CK et al. Liver stiffness-based optimization
of hepatocellular carcinoma risk score in patients with chronic hepati-
tis B. J Hepatol 2014; 60: 339–345
[154] Lee HW, Yoo EJ, Kim BK et al. Prediction of development of liver-related
events by transient elastography in hepatitis B patients with complete
virological response on antiviral therapy. Am J Gastroenterol 2014;
109: 1241–1249
[155] Kim MN, Kim SU, Kim BK et al. Increased risk of hepatocellular carci-
noma in chronic hepatitis B patients with transient elastography-de-
fined subclinical cirrhosis. Hepatology 2015; 61: 1851–1859
[156] Petta S, Vanni E, Bugianesi E et al. The combination of liver stiffness
measurement and NAFLD fibrosis score improves the noninvasive di-
agnostic accuracy for severe liver fibrosis in patients with nonalcoholic
fatty liver disease. Liver Int 2015; 35: 1566–1573
[157] Naveau S, Lamouri K, Pourcher G et al. The diagnostic accuracy of
transient elastography for the diagnosis of liver fibrosis in bariatric
surgery candidates with suspected NAFLD. Obes Surg 2014; 24:
1693–1701
[158] Tapper EB, Challies T, Nasser I et al. The Performance of Vibration
Controlled Transient Elastography in a US Cohort of Patients With
Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2016; 111: 677–
684
[159] Kumar R, Rastogi A, Sharma MK et al. Liver stiffness measurements in
patients with different stages of nonalcoholic fatty liver disease: diag-
nostic performance and clinicopathological correlation. Dig Dis Sci
2013; 58: 265–274
[160] Kwok R, Tse YK, Wong GL et al. Systematic review with meta-analysis:
non-invasive assessment of non-alcoholic fatty liver disease–the role of
transient elastography and plasma cytokeratin-18 fragments. Aliment
Pharmacol Ther 2014; 39: 254–269
[161] Liu H, Fu J, Hong R et al. Acoustic Radiation Force Impulse Elastography
for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic
Fatty Liver Disease Patients: A Systematic Review & Meta-Analysis.
PLoS One 2015; 10: e0127782
[162] Zheng J, Guo H, Zeng J et al. Two-dimensional shear-wave elastogra-
phy and conventional US: the optimal evaluation of liver fibrosis and
cirrhosis. Radiology 2015; 275: 290–300
[163] Boursier J, Vergniol J, Guillet A et al. Diagnostic accuracy and prognos-
tic significance of blood fibrosis tests and liver stiffness measurement
by Fibroscan in non-alcoholic fatty liver disease. J Hepatol 2016; 65:
570–578
[164] Pavlov CS, Casazza G, Nikolova D et al. Transient elastography for di-
agnosis of stages of hepatic fibrosis and cirrhosis in people with alco-
holic liver disease. Cochrane Database Syst Rev 2015; 1: CD010542
[165] Nahon P, Kettaneh A, Tengher-Barna I et al. Assessment of liver fibrosis
using transient elastography in patients with alcoholic liver disease.
J Hepatol 2008; 49: 1062–1068
[166] Nguyen-Khac E, Chatelain D, Tramier B et al. Assessment of asympto-
matic liver fibrosis in alcoholic patients using fibroscan: prospective
comparison with seven non-invasive laboratory tests. Aliment Phar-
macol Ther 2008; 28: 1188–1198
[167] Kim SG, Kim YS, Jung SW et al. The usefulness of transient elastogra-
phy to diagnose cirrhosis in patients with alcoholic liver disease.
Korean J Hepatol 2009; 15: 42–51
[168] Janssens F, de Suray N, Piessevaux H et al. Can transient elastography
replace liver histology for determination of advanced fibrosis in alco-
holic patients: a real-life study. J Clin Gastroenterol 2010; 44: 575–582
[169] Fernandez M, Trepo E, Degre D et al. Transient Elastography using
Fibroscan is the most reliable noninvasive method for the diagnosis of
advanced fibrosis and cirrhosis in alcoholic liver disease. Eur J Gastro-
enterol Hepatol 2015; 27: 1074–1079
[170] Mueller S, Englert S, Seitz HK et al. Inflammation-adapted liver stiff-
ness values for improved fibrosis staging in patients with hepatitis C
virus and alcoholic liver disease. Liver International 2015; 35: 2514–
2521
[171] Cho EJ, Kim MY, Lee JH et al. Diagnostic and Prognostic Values of Non-
invasive Predictors of Portal Hypertension in Patients with Alcoholic
Cirrhosis. PLoS One 2015; 10: e0133935
[172] Sporea I, Ratiu I, Bota S et al. Are different cut-off values of liver stiff-
ness assessed by transient elastography according to the etiology of
liver cirrhosis for predicting significant esophageal varices? Med Ultra-
son 2013; 15: 111–115
[173] Gelsi E, Dainese R, Truchi R et al. Effect of detoxification on liver stiff-
ness assessed by Fibroscan(R) in alcoholic patients. Alcohol Clin Exp
Res 2011; 35: 566–570
[174] Harman DJ, Ryder SD, James MW et al. Direct targeting of risk factors
significantly increases the detection of liver cirrhosis in primary care: a
cross-sectional diagnostic study utilising transient elastography. BMJ
Open 2015; 5: e007516
[175] Bellentani S, Saccoccio G, Costa G et al. Drinking habits as cofactors of
risk for alcohol induced liver damage. Gut 1997; 41: 845–850
[176] Kiani A, Brun V, Laine F et al. Acoustic radiation force impulse imaging
for assessing liver fibrosis in alcoholic liver disease. World J Gastroen-
terol 2016; 22: 4926–4935
[177] Zhang D, Li P, Chen M et al. Non-invasive assessment of liver fibrosis in
patients with alcoholic liver disease using acoustic radiation force im-
pulse elastography. Abdom Imaging 2015; 40: 723–729
[178] Liu F, Wei L, Tang X et al. Clinical value of virtual touch tissue quantifi-
cation and PGA index in evaluation of alcoholic liver fibrosis. Zhong
Nan Da Xue Xue Bao Yi Xue Ban 2015; 40: 1246–1252
[179] Corpechot C, Carrat F, Poujol-Robert A et al. Noninvasive elastography-
based assessment of liver fibrosis progression and prognosis in pri-
mary biliary cirrhosis. Hepatology 2012; 56: 198–208
[180] Corpechot C, El Naggar A, Poujol-Robert A et al. Assessment of biliary
fibrosis by transient elastography in patients with PBC and PSC. Hepa-
tology 2006; 43: 1118–1124
[181] Wang QX, Shen L, Qiu DK et al. Validation of transient elastography
(Fibroscan) in assessment of hepatic fibrosis in autoimmune hepatitis.
Zhonghua Gan Zang Bing Za Zhi 2011; 19: 782–784
[182] Corpechot C, Gaouar F, El Naggar A et al. Baseline values and changes
in liver stiffness measured by transient elastography are associated
with severity of fibrosis and outcomes of patients with primary scle-
rosing cholangitis. Gastroenterology 2014; 146: 970–979 quiz e915–
976
[183] Colecchia A, Di Biase AR, Scaioli E et al. Non-invasive methods can
predict oesophageal varices in patients with biliary atresia after a Kasai
procedure. Dig Liver Dis 2011; 43: 659–663
[184] Righi S, Fiorini E, De Molo C et al. ARFI elastography in patients with
chronic autoimmune liver diseases: A preliminary study. J Ultrasound
2012; 15: 226–231
393Dietrich CF et al. EFSUMB Guidelines and… Ultraschall in Med 2017; 38: 377–394
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 L
a 
Sa
pi
en
za
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
[185] Efe C, Gungoren MS, Ozaslan E et al. Acoustic Radiation Force Impulse
(ARFI) for Fibrosis Staging in Patients with Autoimmune Hepatitis.
Hepatogastroenterology 2015; 62: 670–672
[186] Zhang DK, Chen M, Liu Y et al. Acoustic radiation force impulse elas-
tography for non-invasive assessment of disease stage in patients with
primary biliary cirrhosis: A preliminary study. Clin Radiol 2014; 69:
836–840
[187] Wang X, Qian L, Jia L et al. Utility of Shear Wave Elastography for Dif-
ferentiating Biliary Atresia From Infantile Hepatitis Syndrome. J Ultra-
sound Med 2016; 35: 1475–1479
[188] Shi KQ, Fan YC, Pan ZZ et al. Transient elastography: a meta-analysis of
diagnostic accuracy in evaluation of portal hypertension in chronic
liver disease. Liver Int 2013; 33: 62–71
[189] Robic MA, Procopet B, Metivier S et al. Liver stiffness accurately pre-
dicts portal hypertension related complications in patients with
chronic liver disease: a prospective study. J Hepatol 2011; 55: 1017–
1024
[190] Berzigotti A, Seijo S, Arena U et al. Elastography, spleen size, and pla-
telet count identify portal hypertension in patients with compensated
cirrhosis. Gastroenterology 2013; 144: 102–111
[191] Takuma Y, Nouso K, Morimoto Y et al. Measurement of spleen stiffness
by acoustic radiation force impulse imaging identifies cirrhotic pa-
tients with esophageal varices. Gastroenterology 2013; 144: 92–101
e102
[192] Augustin S, Millan L, Gonzalez A et al. Detection of early portal hyper-
tension with routine data and liver stiffness in patients with asympto-
matic liver disease: a prospective study. J Hepatol 2014; 60: 561–569
[193] Ding NS, Nguyen T, Iser DM et al. Liver stiffness plus platelet count can
be used to exclude high-risk oesophageal varices. Liver Int 2016; 36:
240–245
[194] de Franchis R, Baveno VIF. Expanding consensus in portal hyperten-
sion: Report of the Baveno VI Consensus Workshop: Stratifying risk and
individualizing care for portal hypertension. J Hepatol 2015; 63: 743–
752
[195] Attia D, Schoenemeier B, Rodt T et al. Evaluation of Liver and Spleen
Stiffness with Acoustic Radiation Force Impulse Quantification Elasto-
graphy for Diagnosing Clinically Significant Portal Hypertension. Ult-
raschall in Med 2015; 36: 603–610
[196] Salzl P, Reiberger T, Ferlitsch M et al. Evaluation of portal hypertension
and varices by acoustic radiation force impulse imaging of the liver
compared to transient elastography and AST to platelet ratio index.
Ultraschall in Med 2014; 35: 528–533
[197] Takuma Y, Nouso K, Morimoto Y et al. Portal Hypertension in Patients
with Liver Cirrhosis: Diagnostic Accuracy of Spleen Stiffness. Radiology
2016; 279: 609–619
[198] Elkrief L, Rautou PE, Ronot M et al. Prospective Comparison of Spleen
and Liver Stiffness by Using Shear-Wave and Transient Elastography for
Detection of Portal Hypertension in Cirrhosis. Radiology 2015; 275:
589–598
[199] Kim TY, Jeong WK, Sohn JH et al. Evaluation of portal hypertension by
real-time shear wave elastography in cirrhotic patients. Liver Int 2015;
35: 2416–2424
[200] Jansen C, Bogs C, Verlinden W et al. Algorithm to rule out clinically
significant portal hypertension combining Shear-wave elastography of
liver and spleen: a prospective multicentre study. Gut 2016; 65:
1057–1058. DOI: 10.1136/gutjnl-2016-311536
[201] Choi SY, Jeong WK, Kim Y et al. Shear-Wave Elastography: A Noninva-
sive Tool for Monitoring Changing Hepatic Venous Pressure Gradients
in Patients with Cirrhosis. Radiology 2014; 273: 917–926
394 Dietrich CF et al. EFSUMB Guidelines and… Ultraschall in Med 2017; 38: 377–394
Guidelines & Recommendations
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 L
a 
Sa
pi
en
za
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
